G-BA criticises submitted data for assessments of pralsetinib and idecabtagen vicleucel
On 16 June 2022, the G-BA published its findings on the benefit assessments of Gavreto (pralsetinib) and Abecma (idecabtagen vicleucel). Both drugs
Category: Uncategorized
Happy Holidays!
Here is my last blog post of the year. Somehow we’ve come to the end of another year. Most of us are